<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rospedj</journal-id><journal-title-group><journal-title xml:lang="ru">Российский педиатрический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Pediatric Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2687-0843</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15690/rpj.v1i4.2190</article-id><article-id custom-type="elpub" pub-id-type="custom">rospedj-78</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Модель прогнозирования тромботических осложнений после операций на сердце у детей</article-title><trans-title-group xml:lang="en"><trans-title>A prognostic model for thrombotic complications after pediatric cardiac surgery</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3395-2812</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ластовка</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lastovka</surname><given-names>Vasily A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ластовка Василий Анатольевич, врач анестезиолог-реаниматолог</p><p>119991, Москва, Ломоносовский пр-т, д. 2, стр. 1 </p></bio><bio xml:lang="en"/><email xlink:type="simple">richard-brabant@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6667-9472</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тепаев</surname><given-names>Р. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Tepaev</surname><given-names>Rustem F.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8311-9506</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гордеева</surname><given-names>О. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Gordeeva</surname><given-names>Olga B.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Биджиев</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Bidzhiev</surname><given-names>Anuar R.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр здоровья детей Министерства Здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Children’s Health</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр здоровья детей Министерства Здравоохранения Российской Федерации;&#13;
Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Children’s Health;&#13;
I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>РНИМУ им. Н.И. Пирогова Минздрава России;&#13;
НИИ Педиатрии и охраны здоровья детей ЦКБ РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University;&#13;
Research Institute of Pediatrics and Health Protection of Children, Central Clinical Hospital of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр здоровья детей Министерства Здравоохранения Российской Федерации;&#13;
НИИ Педиатрии и охраны здоровья детей ЦКБ РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Children’s Health;&#13;
Research Institute of Pediatrics and Health Protection of Children, Central Clinical Hospital of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>01</month><year>2021</year></pub-date><volume>1</volume><issue>4</issue><fpage>11</fpage><lpage>17</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ластовка В.А., Тепаев Р.Ф., Гордеева О.Б., Биджиев А.Р., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ластовка В.А., Тепаев Р.Ф., Гордеева О.Б., Биджиев А.Р.</copyright-holder><copyright-holder xml:lang="en">Lastovka V.A., Tepaev R.F., Gordeeva O.B., Bidzhiev A.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rospedj.ru/jour/article/view/78">https://www.rospedj.ru/jour/article/view/78</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Проведение операций на сердце в условиях искусственного кровообращения (ИК) у детей сопровождается гемодилюцией, гипотермией, контактом крови с искусственными поверхностями, а также операционной травмой. Все это приводит к повреждению клеток эндотелия, агрегации и дегрануляции тромбоцитов, активации системы врожденного иммунитета, развитию системного воспаления, потреблению факторов свертывающей, противосвертывающей и фибринолитической систем, что в конечном итоге ассоциируется с развитием тромботических осложнений.</p></sec><sec><title>Цель</title><p>Цель. На основе изучения клинических и лабораторных параметров создать математическую модель прогнозирования тромботических осложнений у детей после ИК.</p></sec><sec><title>Методы</title><p>Методы. В нашей работе были изучены клинические и лабораторные данные 153 детей в возрасте от рождения до 11 мес 29 дней, оперированных в условиях ИК по поводу врожденных пороков сердца (ВПС). У всех пациентов изучены общеклинические и лабораторные показатели: клинический анализ крови, биохимический анализ крови, скрининговые показатели коагулограммы, концентрация D-димера, активность фактора фон Виллебранда, антитромбина III, плазминогена, протеинов С и S, альфа-2- антиплазмина, активируемого тромбином ингибитора фибринолиза (thrombin activatable fibrinolysis inhibitor; TAFI), и фибрин-мономер.</p></sec><sec><title>Результаты</title><p>Результаты. У 43 пациентов диагностированы тромбозы в послеоперационном периоде, что составляет 28,1%. При обследовании детей были выявлены тромбозы различной локализации: внутрисердечные, нарушения мозгового кровообращения по ишемическому типу, ишемия конечностей и т. д. При проведении логистического регрессионного анализа построена модель развития тромботических осложнений, в которую вошло 4 параметра: активность лактатдегидрогеназы (ЛДГ), активность TAFI, активность фактора фон Виллебранда, активность протеина С. Чувствительность модели составила 95,3%, а специфичность – 96,4%.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Cardiac surgery performed on pediatric patients with the use of artificial blood circulation (ABC) is accompanied by hemodilution, hypothermia and blood contact with artificial surfaces, as well as surgical trauma. All the above lead to endothelial cell injury, platelet aggregation and degranulation, activation of innate immunity, development of systemic inflammation and consumption of clotting, anti-coagulation and fibrinolytic factors, which is ultimately associated with the occurrence of thrombotic complications.</p></sec><sec><title>Objective</title><p>Objective. The study aimed at developing a mathematical model for the prognosis of thrombotic complications in children which had undergone the ABC, based on assessment of their clinical and laboratory parameters.</p></sec><sec><title>Methods</title><p>Methods. We have assessed clinical and laboratory data obtained from 153 children (newborn to 11 months 29 days of age) which had undergone cardiac surgery under conditions of ABC due to congenital heart defects (CHD). For all patients the general clinical and laboratory parameters: complete blood count, comprehensive metabolic panel, parameters of screening coagulogram, D-dimer concentration, von Willebrand factor activity, levels of antithrombin III, plasminogen, protein C and protein S, alpha-2-antiplasmin, thrombin activatable fibrinolysis inhibitor (TAFI) and fibrin-monomer have been assessed.</p></sec><sec><title>Results</title><p>Results. In 43 patients (28.1%) post-operative thromboses have been diagnosed. Examination of children revealed the presence of thrombosis of various localization including the intracardiac thrombi, ischemic cerebrovascular events, limb ischemia, etc. Based on logistic regression analysis, a model of development of thrombotic complications has been built which included 4 parameters: activity of lactate dehydrogenase (LDH), TAFI activity, von Willebrand factor activity and protein C activity. Model sensitivity was 95.3%, and its specificity — 96.4%.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>тромбоз</kwd><kwd>искусственное кровообращение</kwd><kwd>врожденные пороки сердца</kwd><kwd>ЛДГ</kwd><kwd>фактор фон Виллебранда</kwd><kwd>протеин С</kwd><kwd>TAFI</kwd></kwd-group><kwd-group xml:lang="en"><kwd>thrombosis</kwd><kwd>assisted circulation</kwd><kwd>congenital heart defects</kwd><kwd>LDH</kwd><kwd>von Willebrand factor</kwd><kwd>protein C</kwd><kwd>TAFI</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Отсутствует</funding-statement><funding-statement xml:lang="en">Not specified</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cholette JM, Rubenstein JS, Alfieris GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg. 2007;84(4):1320–1325. doi: 10.1016/j.athoracsur.2007.05.026.</mixed-citation><mixed-citation xml:lang="en">Cholette JM, Rubenstein JS, Alfieris GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg. 2007;84(4):1320–1325. doi: 10.1016/j.athoracsur.2007.05.026.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Odegard KC, McGowan FX Jr, Zurakowski D, et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg. 2003;125(6): 1260–1267. doi: 10.1016/s0022-5223(02)73605-2.</mixed-citation><mixed-citation xml:lang="en">Odegard KC, McGowan FX Jr, Zurakowski D, et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg. 2003;125(6): 1260–1267. doi: 10.1016/s0022-5223(02)73605-2.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Odegard KC, McGowan FX Jr, Zurakowski D, et al. Coagulation factor abnor-malities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann Thorac Surg. 2002;73(6):1770–1777. doi: 10.1016/s0003-4975(02)03580-4.</mixed-citation><mixed-citation xml:lang="en">Odegard KC, McGowan FX Jr, Zurakowski D, et al. Coagulation factor abnor-malities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann Thorac Surg. 2002;73(6):1770–1777. doi: 10.1016/s0003-4975(02)03580-4.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Horigome H, Hiramatsu Y, Shigeta O, et al. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol. 2002;39(6):1072–1077. doi: 10.1016/s0735-1097(02)01718-7.</mixed-citation><mixed-citation xml:lang="en">Horigome H, Hiramatsu Y, Shigeta O, et al. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol. 2002;39(6):1072–1077. doi: 10.1016/s0735-1097(02)01718-7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Odegard KC, Zurakowski D, Hornykewycz S, et al. Evaluation of the coagulation system in children with two-ventricle congenital heart disease. Ann Thorac Surg. 2007;83(5):1797–1803. doi: 10.1016/j.athoracsur.2006.12.030.</mixed-citation><mixed-citation xml:lang="en">Odegard KC, Zurakowski D, Hornykewycz S, et al. Evaluation of the coagulation system in children with two-ventricle congenital heart disease. Ann Thorac Surg. 2007;83(5):1797–1803. doi: 10.1016/j.athoracsur.2006.12.030.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Manlhiot C, Menjak IB, Brandao LR, et al. Risk, clinical features and outcomes of thrombosis associated with pediatric cardiac surgery. Circulation. 2011;124(14):1511–1519. doi: 10.1161/CIRCULATIONAHA.110.006304.</mixed-citation><mixed-citation xml:lang="en">Manlhiot C, Menjak IB, Brandao LR, et al. Risk, clinical features and outcomes of thrombosis associated with pediatric cardiac surgery. Circulation. 2011;124(14):1511–1519. doi: 10.1161/CIRCULATIONAHA.110.006304.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gottesman RF, Sherman PM, Grega MA, et al. Watershed strokes after cardiac surgery: diagnosis, etiology, and outcome. Stroke. 2006;37(9): 2306–2311. doi: 10.1161/01.STR.0000236024.68020.3a.</mixed-citation><mixed-citation xml:lang="en">Gottesman RF, Sherman PM, Grega MA, et al. Watershed strokes after cardiac surgery: diagnosis, etiology, and outcome. Stroke. 2006;37(9): 2306–2311. doi: 10.1161/01.STR.0000236024.68020.3a.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Silvey M, Hall M, Bilynsky E, Carpenter SL. Increasing rates of thrombosis in children with congenital heart disease undergoing cardiac surgery. Thromb Res. 2018;162:15–21. doi: 10.1016/j.thromres.2017.12.009.</mixed-citation><mixed-citation xml:lang="en">Silvey M, Hall M, Bilynsky E, Carpenter SL. Increasing rates of thrombosis in children with congenital heart disease undergoing cardiac surgery. Thromb Res. 2018;162:15–21. doi: 10.1016/j.thromres.2017.12.009.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zabala LM, Guzzetta NA. Cyanotic congenital heart disease (CCHD): focus on hypoxemia, secondary erythrocytosis, and coagulation alterations. Paediatr Anaesth. 2015;25(10): 981–989. doi: 10.1111/pan.12705.</mixed-citation><mixed-citation xml:lang="en">Zabala LM, Guzzetta NA. Cyanotic congenital heart disease (CCHD): focus on hypoxemia, secondary erythrocytosis, and coagulation alterations. Paediatr Anaesth. 2015;25(10): 981–989. doi: 10.1111/pan.12705.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gursoy T, Tekinalp G, Yigit S, et al. Thrombin activatable fibrinolysis inhibitor activity (TAFIa) levels in neonates with meconium-stained amniotic fluid. J Matern Fetal Neonatal Med. 2008;21(2):123–128. doi: 10.1080/14767050801891135.</mixed-citation><mixed-citation xml:lang="en">Gursoy T, Tekinalp G, Yigit S, et al. Thrombin activatable fibrinolysis inhibitor activity (TAFIa) levels in neonates with meconium-stained amniotic fluid. J Matern Fetal Neonatal Med. 2008;21(2):123–128. doi: 10.1080/14767050801891135.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273(5):2792–2798. doi: 10.1074/jbc.273.5.2792.</mixed-citation><mixed-citation xml:lang="en">Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273(5):2792–2798. doi: 10.1074/jbc.273.5.2792.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost. 2003;1(7):1566– 1574. doi: 10.1046/j.1538-7836.2003.00329.x.</mixed-citation><mixed-citation xml:lang="en">Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost. 2003;1(7):1566– 1574. doi: 10.1046/j.1538-7836.2003.00329.x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Emani S, Zurakowski D, Baird CW, et al. Hypercoagulability markers predict thrombosis in single ventricle neonates undergoing cardiac surgery. 2013;96(2):651–656. doi: 10.1016/j.athoracsur.2013.04.061.</mixed-citation><mixed-citation xml:lang="en">Emani S, Zurakowski D, Baird CW, et al. Hypercoagulability markers predict thrombosis in single ventricle neonates undergoing cardiac surgery. 2013;96(2):651–656. doi: 10.1016/j.athoracsur.2013.04.061.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–494. doi: 10.1038/35097008.</mixed-citation><mixed-citation xml:lang="en">Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–494. doi: 10.1038/35097008.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662–1666. doi: 10.1182/blood.v98.6.1662.</mixed-citation><mixed-citation xml:lang="en">Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662–1666. doi: 10.1182/blood.v98.6.1662.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98(6):1654–1661. doi: 10.1182/blood.v98.6.1654.</mixed-citation><mixed-citation xml:lang="en">Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98(6):1654–1661. doi: 10.1182/blood.v98.6.1654.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving pro-tease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059–41063. doi: 10.1074/jbc.C100515200.</mixed-citation><mixed-citation xml:lang="en">Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving pro-tease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059–41063. doi: 10.1074/jbc.C100515200.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hunt R, Hoffman CM, Emani S, et al. Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease. J Thromb Haemost. 2017;15(12):2306–2316. doi: 10.1111/jth.13860.</mixed-citation><mixed-citation xml:lang="en">Hunt R, Hoffman CM, Emani S, et al. Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease. J Thromb Haemost. 2017;15(12):2306–2316. doi: 10.1111/jth.13860.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C, protease activated receptor 1, and neuroprotection. Blood. 2018;132(2): 159–169. doi: 10.1182/blood-2018-02-769026.</mixed-citation><mixed-citation xml:lang="en">Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C, protease activated receptor 1, and neuroprotection. Blood. 2018;132(2): 159–169. doi: 10.1182/blood-2018-02-769026.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Жарков П. А., Полетаев А. В., Грачёва М. А. и др. Применение метода «Тромбориск» у детей с тромбозом глубоких вен // Доктор.Ру. Гематология. — 2016. — № 5(122). — С. 48–51.</mixed-citation><mixed-citation xml:lang="en">Zharkov PA, Poletaev AV, Gratcheva MA. ThromboPath Assay for Assessment of Hemostasis in Children with Deep Vein Thrombosis. Doctor.Ru. Hematology. 2016;(5(122)):48–51. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Гончаров А. А., Рыбка М. М., Хинчагов Д. Я., Рогальская Е. А. Cлучай интраоперационного выявления дефицита протеина C у больного, оперированного по поводу цианотического порока сердца // Гематология и трансфузиология. — 2020. — Т. 65. — № 1. — С. 61–69. doi: 10.35754/02345730-2020-65-1-61-69.</mixed-citation><mixed-citation xml:lang="en">Goncharov АA, Rybka MM, Khinchagov DYa, Rogalskaya EA. A clinical case of protein C defi ciency revealed in a patient during surgery for cyanotic heart defect. Russian Journal of Hematology and Transfusiology = Gematologiya i transfuziologiya. 2020;65(1):61–69. (In Russ). doi: 10.35754/02345730-2020-65-1-61-69.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Шифрин Ю. А., Жарков П. П., Пашанов Е. Д. Применение концентрата протеина С у детей с приобретенным его дефицитом // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. — 2019. — Т. 18. — № 2. — С. 59–65. doi: 10.24287/1726-1708-2019-18-2-59-65.</mixed-citation><mixed-citation xml:lang="en">Shifrin IA, Zharkov PV, Pashanov ED, et al. Pediatric hematology/oncology and immunopathology. 2019;18(2):59–65. (In Russ). doi: 10.24287/1726-1708-2019-18-2-59-65.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Siegerink B. FVIII, Protein C and the Risk of Arterial Thrombosis: More than the Sum of Its Parts. Thromb Haemost. 2018;118(7):1127–1129. doi:10.1055/s-0038-1661373.</mixed-citation><mixed-citation xml:lang="en">Siegerink B. FVIII, Protein C and the Risk of Arterial Thrombosis: More than the Sum of Its Parts. Thromb Haemost. 2018;118(7):1127–1129. doi:10.1055/s-0038-1661373.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Abd El Mabood S, Fahmy DM, Akef A, El Sallab S. Protein C and Anti-Thrombin-III Deficiency in Children With Beta-Thalassemia. J Hematol. 2018;7(2):62–68. doi:10.14740/jh392w.</mixed-citation><mixed-citation xml:lang="en">Abd El Mabood S, Fahmy DM, Akef A, El Sallab S. Protein C and Anti-Thrombin-III Deficiency in Children With Beta-Thalassemia. J Hematol. 2018;7(2):62–68. doi:10.14740/jh392w.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557536. Accessed on December 11, 2020.</mixed-citation><mixed-citation xml:lang="en">Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK557536. Accessed on December 11, 2020.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
